TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00650897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10-20 mg once daily
Study: NCT02561104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional manual phacoemulsification
Study: NCT04629586

Intervention type: OTHER
Intervention: No intervention
Description: Observational research study
Study: NCT01605890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine / tenofovir disoproxil fumarate / raltegravir .
Description: emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID.
Study: NCT00130494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT00598806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
Study: NCT02190708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single oral dose on day1 and day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: single oral dose on day1 and day6
Study: NCT03486600

Intervention type: OTHER
Group type: OTHER
Intervention: Fluid Resuscitation
Description: Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
Study: NCT00163046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
Study: NCT00598806

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor
Study: NCT03345173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581-a
Description: Two infusions in the context of naltrexone induction protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CI-581-b
Description: Two infusions in the context of naltrexone induction protocol.
Study: NCT02314286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02277236

Intervention type: RADIATION
Intervention: DXA scanning
Description: Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
Study: NCT00574041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: injected, once a week
Study: NCT02277236

Intervention type: RADIATION
Intervention: DXA scanning
Description: Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).

Intervention type: RADIATION
Intervention: CT imaging
Description: Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).

Intervention type: RADIATION
Intervention: CT imaging
Description: Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
Study: NCT00938197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan (1d\~7d) Amlodipine (12d\~14d) Fimasartan + Amlodipine(15d\~21d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine (1d\~10d) Amlodipine (25d\~27d) Fimasartan + Amlodipine(28d\~34d)
Study: NCT05243147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal stents
Description: using nasal stents after septoplasty

Intervention type: DEVICE
Group type: OTHER
Intervention: merocel
Description: using merocel after septoplasty
Study: NCT01966276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl-P plus Nutrient Formula
Description: * Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P (5mg)~ * Four tablets of CFS Nutrient Formula~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P (10mg)~ * Four tablets of CFS Nutrient Formula

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methyl-P plus Nutrient matched placebos
Description: * Week 1 (take the following together twice a day-at breakfast and lunch)~  * One tablet of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo~* Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~  * Two tablets of Methyl-P Placebo~ * Four tablets of CFS Nutrient Placebo
Study: NCT04724772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Injection of tranexamic acid preoperatively
Study: NCT02415504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced care transition
Description: Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care transition
Description: Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
Study: NCT05001581

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic partial repair of massive rotator cuff tear
Description: Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic partial repair of rotator cuff with biceps augmentation
Description: Surgery relies on arthroscopic reconstruction of the rotator cuff tendons. Because of irreparability of Supraspinatus tendon ( always) and infraspinatus tendon ( sometimes) surgeon performed partial repair to cover humeral head by the tendons and because of good quality of the long head of the biceps tendon, its uses as biological reinforcement of the reconstruction to achieve better clinical and radiological outcome
Study: NCT00574041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: injected, once a week
Study: NCT00163046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime for 28 days
Study: NCT03886194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional treatment in pulmonary
Description: Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interventional treatment in pulmonary
Description: Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
Study: NCT00988052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: One capsule containing 0.6 mg laquinimod to be administered orally once daily.
Study: NCT02223052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
Study: NCT00056966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANTI-CD45
Description: 400ug/kg Day-5 through Day-2
Study: NCT02223052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: 75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: 75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: 75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza
Description: 75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
Study: NCT03202498

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4g Placebo
Description: Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8g Yaq-001
Description: Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 8g Placebo
Description: Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
Study: NCT00542854

Intervention type: DEVICE
Intervention: MP3
Description: 4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
Study: NCT02471430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha2a
Description: Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha2a
Description: Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
Study: NCT04489680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational
Description: Teaching session
Study: NCT02716454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileocaecal resection
Description: laparoscopic ileocaecal resection with primary anastomosis
Study: NCT04173468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moblization with Movement
Description: patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan knee taping
Description: patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
Study: NCT01581814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg of Metformin per 3/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin;
Description: 1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin plus Yasmin
Description: 0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
Study: NCT01761890

Intervention type: BEHAVIORAL
Intervention: Dasatinib discontinuation
Description: Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
Study: NCT04083053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perianal Exam
Description: Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perianal Exam
Description: Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
Study: NCT00849355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCOMP-14 + rituximab
Description: Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d.
Study: NCT00681395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: once daily for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-143
Description: once daily for 6 days
Study: NCT04083053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-resolution anoscopy (HRA) with biopsy
Description: The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-resolution anoscopy (HRA) with biopsy
Description: The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
Study: NCT03120416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: 12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
Study: NCT02155608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active eTNS
Description: Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham eTNS
Description: Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
Study: NCT00005640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative Endoscopy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99m Sulfur Colloid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Probe

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Sentinel Lymph Nodes
Study: NCT02454894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: surface anesthesia with lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: surface anesthesia with lidocaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postoperative management
Description: lying without the pillow for half an hour after lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postoperative management
Description: lying without the pillow for half an hour after lumbar puncture
Study: NCT01045876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
Study: NCT02433691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simultaneous aerobic exercise
Description: stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sequential aerobic exercise
Description: stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stretching and toning
Description: anaerobic stretching and toning followed by memory training.
Study: NCT03325010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study: NCT03495362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast Beta-glucan
Description: Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study: NCT02102906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
Study: NCT02759432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training
Study: NCT02132091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
Study: NCT03325010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: non-active dosage form
Study: NCT03674294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant is manufactured by Merck \& Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.